In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warning On Sleep Aids/Muscle Builders With 1,4 Butanediol Issued

This article was originally published in The Tan Sheet

Executive Summary

Products containing 1,4 butanediol marketed as dietary supplement sleep aids and muscle builders have been linked to "at least" three deaths and several "severe" adverse reactions, FDA says in a "Talk Paper" and consumer warning issued May 11.

You may also be interested in...



GBL Would Become A DEA Controlled Substance Under House Date Rape Bill

Gamma butyrolactone (GBL) would be classified as a controlled substance under the proposed Hillary J. Farias Date-Rape Prevention Drug Act. The bill (HR 2130), introduced June 10 by Rep. Fred Upton (R-Mich.), unanimously passed the House Commerce/ Health Subcommittee at a mark-up July 27. Senate companion legislation is being drafted; the House bill is expected to go before the full Commerce Committee in the next few weeks.

GBL Would Become A DEA Controlled Substance Under House Date Rape Bill

Gamma butyrolactone (GBL) would be classified as a controlled substance under the proposed Hillary J. Farias Date-Rape Prevention Drug Act. The bill (HR 2130), introduced June 10 by Rep. Fred Upton (R-Mich.), unanimously passed the House Commerce/ Health Subcommittee at a mark-up July 27. Senate companion legislation is being drafted; the House bill is expected to go before the full Commerce Committee in the next few weeks.

GBL Would Become A DEA Controlled Substance Under House Date Rape Bill

Gamma butyrolactone (GBL) would be classified as a controlled substance under the proposed Hillary J. Farias Date-Rape Prevention Drug Act. The bill (HR 2130), introduced June 10 by Rep. Fred Upton (R-Mich.), unanimously passed the House Commerce/ Health Subcommittee at a mark-up July 27. Senate companion legislation is being drafted; the House bill is expected to go before the full Commerce Committee in the next few weeks.

Topics

UsernamePublicRestriction

Register

PS089809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel